Response

Affiliations

¹ Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA. Electronic address: maulin.patel@tuhs.temple.edu.
² Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
³ Department of Hematology and Oncology, Temple University Hospital, Philadelphia, PA.
⁴ Department of Rheumatology, Temple University Hospital, Philadelphia, PA.

Comment

Maulin Patel et al. Chest. 2021 Apr.

. 2021 Apr;159(4):1679.

doi: 10.1016/j.chest.2020.11.035. Epub 2021 Apr 6.

¹ Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA. Electronic address: maulin.patel@tuhs.temple.edu.
² Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
³ Department of Hematology and Oncology, Temple University Hospital, Philadelphia, PA.
⁴ Department of Rheumatology, Temple University Hospital, Philadelphia, PA.

No abstract available

Comment on

Etoposide as Salvage Therapy for Cytokine Storm Due to Coronavirus Disease 2019.
Patel M, Dominguez E, Sacher D, Desai P, Chandar A, Bromberg M, Caricchio R, Criner GJ; Temple University COVID-19 Research Group. Patel M, et al. Chest. 2021 Jan;159(1):e7-e11. doi: 10.1016/j.chest.2020.09.077. Epub 2020 Sep 12. Chest. 2021. PMID: 32931823 Free PMC article.
Etoposide for Cytokine Storm Because of Coronavirus Disease 2019.
Delgado-López PD, Buzón-Martín L, Montero-Baladia M, Astigarraga I. Delgado-López PD, et al. Chest. 2021 Apr;159(4):1678-1679. doi: 10.1016/j.chest.2020.10.090. Epub 2021 Apr 6. Chest. 2021. PMID: 34021998 Free PMC article. No abstract available.

1. Patel M., Dominguez E., Sacher D., et al. the Temple University COVID-19 Research Group Etoposide as salvage therapy for cytokine storm due to coronavirus disease 2019. Chest. 2021;159(1):e7–e11. - PMC - PubMed
1. Montero-Baladía M., Buzón L., Astigarraga I., et al. Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients. J Infect. 2020;81(3):452–482. - PMC - PubMed
1. National Institutes of Health Clinical Center. A phase II single-center, randomized, open-label, safety and efficacy study of etoposide in patients with COVID-19 infection. NCT04356690. ClinicalTrials.gov. National Institutes of Health; 2020. Updated September 4, 2020. http://clinicaltrials.gov/ct2/show/ NCT04356690. NCT04356690.